Literature DB >> 28782118

Undetectable negative tissue transglutaminase IgA antibodies predict mucosal healing in treated coeliac disease patients.

H Fang1, K S King2, J J Larson2, M R Snyder3, T T Wu4, M J Gandhi5, J A Murray6.   

Abstract

BACKGROUND: Tissue transglutaminase (tTG) immunoglobulin A (IgA) testing is a sensitive adjunct to the diagnosis of coeliac disease. The threshold for positivity was developed for diagnosis, with negative results reported as below the reference value (<4 U/mL). AIM: To investigate if an undetectable (tTG IgA<1.2 U/mL) is more predictive of healing compared to patients with negative but detectable serology (1.2-3.9 U/mL).
METHODS: We performed a retrospective study of 402 treated coeliac disease patients seen at the Mayo Clinic with negative tTG IgA values drawn within 1 month of duodenal biopsy between January 2009 and December 2015. The Corazza-Villanacci score was used to assess mucosal healing. The presence of gastrointestinal symptoms was also collected. Logistic regression was used to assess the relationship of clinical variables with a normal biopsy.
RESULTS: Patients with undetectable titres more frequently had normal duodenal histology compared to patients with detectable tTG IgA levels (117/240 vs. 53/162; OR=1.96; 1.292, 2.961). Asymptomatic patients more frequently had normal duodenum as compared to symptomatic patients (88/163 vs. 82/239; OR=2.25; CI: 1.494, 3.377). Patients with undetectable serology and on a gluten-free diet for ≥2 years were more likely to have no villous atrophy compared to patients with detectable serology (148/192 vs. 55/88; OR=2.02; CI: 1.17, 3.49).
CONCLUSION: In subjects recovering from coeliac disease with negative tTG IgA serology, an undetectable titre is associated with normal histology on follow-up biopsy.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28782118     DOI: 10.1111/apt.14250

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  Prospective longitudinal study: use of faecal gluten immunogenic peptides to monitor children diagnosed with coeliac disease during transition to a gluten-free diet.

Authors:  Isabel Comino; Verónica Segura; Luis Ortigosa; Beatríz Espín; Gemma Castillejo; José Antonio Garrote; Carlos Sierra; Antonio Millán; Carmen Ribes-Koninckx; Enriqueta Román; Alfonso Rodríguez-Herrera; Jacobo Díaz; Jocelyn Anne Silvester; Ángel Cebolla; Carolina Sousa
Journal:  Aliment Pharmacol Ther       Date:  2019-05-10       Impact factor: 8.171

2.  A Call for Research on the Prognostic Role of Follow-Up Histology in Celiac Disease: A Systematic Review.

Authors:  Zsolt Szakács; Noémi Gede; Zoltán Gyöngyi; Margit Solymár; Dezső Csupor; Bálint Erőss; Áron Vincze; Alexandra Mikó; Andrea Vasas; László Szapáry; Dalma Dobszai; Viktória Balikó; Roland Hágendorn; Péter Hegyi; Judit Bajor
Journal:  Front Physiol       Date:  2019-11-19       Impact factor: 4.566

3.  Non-invasive prediction of persistent villous atrophy in celiac disease.

Authors:  Barbora Packova; Petra Kovalcikova; Zdenek Pavlovsky; Daniel Bartusek; Jitka Prokesova; Jiri Dolina; Radek Kroupa
Journal:  World J Gastroenterol       Date:  2020-07-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.